China’s life sciences ecosystem is entering a new phase of innovation — driven not only by breakthrough science, but also by the rapid evolution of research tools, platforms, and enabling technologies. The overhang from COVID have pretty much been absorbed. In my new video, we explore:How research tools and enablers are accelerating innovationWhere value is being created across the life sciences value chainWhat this momentum means for companies navigating China’s evolving landscape Watch the fu ...

L.E.K. Consulting

The "11th batch" or the 2025 pharmaceutical volume-based procurement (VBP) results are out. This VBP is reshaping pharma pricing and competitive landscape in China — and it’s here to stay. In my recent video briefing, I explain why and share a three-phase playbook to preserve brand value as volumes and margins tighten.What the data shows ∙ Average drug prices down 50%+ ∙ US$60B (now even higher!) in system savings ∙ ~80% of savings redirected to innovative therapiesHow to respond — three phase ...

L.E.K. Consulting

Want to hear my favorite licensing example between a multinational pharma and a Chinese biotech? I use this example in my new L.E.K. Consulting video briefing, to explain why partnerships and licensing deals are becoming the preferred route to market using specific industry examples. I also highlight how the right partnerships can accelerate pipelines, expand portfolios, and strengthen therapeutic area leadership. Even though China is the world’s second-largest pharmaceutical market, bringing ...

L.E.K. Consulting